These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24762070)

  • 1. PROSTVAC® targeted immunotherapy candidate for prostate cancer.
    Shore ND
    Immunotherapy; 2014; 6(3):235-47. PubMed ID: 24762070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of PROSTVAC immunotherapy in prostate cancer.
    Singh P; Pal SK; Alex A; Agarwal N
    Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in prostate cancer.
    Sobol I; Thompson RH; Dong H; Krco C; Kwon ED
    Curr Urol Rep; 2015 Jun; 16(6):34. PubMed ID: 25894495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer vaccines in clinical trials.
    Lubaroff DM
    Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.
    Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Kim HL; Nguyen MN; Gulley JL; Jamieson C; Hsu P; Wojtowicz M; Parnes H; Schlom J; Dahut WL; Madan RA; Donahue RN; Chow HS
    Eur Urol Focus; 2018 Sep; 4(5):636-638. PubMed ID: 30197041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
    Kantoff PW; Schuetz TJ; Blumenstein BA; Glode LM; Bilhartz DL; Wyand M; Manson K; Panicali DL; Laus R; Schlom J; Dahut WL; Arlen PM; Gulley JL; Godfrey WR
    J Clin Oncol; 2010 Mar; 28(7):1099-105. PubMed ID: 20100959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccines for prostate cancer.
    Cha E; Fong L
    Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in immunotherapy for the treatment of prostate cancer.
    Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
    Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of high risk metastatic prostate cancer: the case for novel therapies.
    Brand TC; Tolcher AW
    J Urol; 2006 Dec; 176(6 Pt 2):S76-80; discussion S81-2. PubMed ID: 17084174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
    Madan RA; Bilusic M; Heery C; Schlom J; Gulley JL
    Semin Oncol; 2012 Jun; 39(3):296-304. PubMed ID: 22595052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM; Gulley JL; Madan RA
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.